Company press releases

Displaying 1 - 32 of 32 results
Released Company Title Industry Topic
09 Feb 2021
08:48 CET 		IMMUPHARMA ImmuPharma - Lupuzor™ scheduled to commence international Phase 3 trial in Lupus patients in H2 2021 20103010 Biotechnology Products and services
18 Jan 2021
10:24 CET 		IMMUPHARMA ImmuPharma - Appointment of Company Secretary 20103010 Biotechnology Corporate life
04 Jan 2021
08:55 CET 		IMMUPHARMA ImmuPharma - Lanstead TR1 20103010 Biotechnology Change in Capital
02 Dec 2020
14:59 CET 		IMMUPHARMA IMMUPHARMA TO PRESENT AT BIOTECH SHOWCASE™ DIGITAL 2021 20103010 Biotechnology Other subject
26 Nov 2020
08:27 CET 		IMMUPHARMA ImmuPharma - Grant of Share Options & PDMR dealing 20103010 Biotechnology Other subject
23 Nov 2020
08:43 CET 		IMMUPHARMA ImmuPharma - Conversion of Convertible Security 20103010 Biotechnology Change in Capital
20 Nov 2020
09:21 CET 		IMMUPHARMA ImmuPharma - FDA confirms 4 December 2020 for Type ‘A’ meeting to discuss guidance on forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients 20103010 Biotechnology Products and services
10 Nov 2020
08:55 CET 		IMMUPHARMA IMMUPHARMA - Update on submission to the FDA for the forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients 20103010 Biotechnology Products and services
30 Sep 2020
08:54 CEST 		IMMUPHARMA ImmuPharma - Interim results for the six months ended 30 June 2020 20103010 Biotechnology Other subject
30 Sep 2020
08:52 CEST 		IMMUPHARMA ImmuPharma - Total Share Capital Notification - Admission to trading on Euronext Growth Brussels of newly issued ordinary shares 20103010 Biotechnology Change in Capital
29 Sep 2020
09:16 CEST 		IMMUPHARMA ImmuPharma - Share Subscription into Incanthera plc 20103010 Biotechnology Other subject
22 Sep 2020
08:46 CEST 		IMMUPHARMA ImmuPharma - Repayment of Convertible Security 20103010 Biotechnology Change in Capital
11 Sep 2020
10:48 CEST 		IMMUPHARMA ImmuPharma - Update on submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients 20103010 Biotechnology Products and services
10 Sep 2020
13:27 CEST 		IMMUPHARMA ImmuPharma - Conversion of Convertible Security 20103010 Biotechnology Change in Capital
09 Sep 2020
16:50 CEST 		IMMUPHARMA ImmuPharma - Conversion of Convertible Security 20103010 Biotechnology Change in Capital
07 Sep 2020
08:45 CEST 		IMMUPHARMA ImmuPhartma - Placing to raise £6.5 million – update ; related party transaction 20103010 Biotechnology Change in Capital
03 Sep 2020
09:07 CEST 		IMMUPHARMA ImmuPharma - Conversion of Convertible Security 20103010 Biotechnology Change in Capital
02 Sep 2020
08:31 CEST 		IMMUPHARMA ImmuPharma - Placing to raise £6.5 million 20103010 Biotechnology Change in Capital
27 Jul 2020
09:27 CEST 		IMMUPHARMA ImmuPharma - Submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients 20103010 Biotechnology Other subject
11 Jun 2020
08:40 CEST 		IMMUPHARMA STRATEGIC INVESTMENTS FROM TWO SPECIALIST US HEALTHCARE INVESTORS 20103010 Biotechnology Other subject
05 Jun 2020
08:50 CEST 		IMMUPHARMA Notification of Change of Registered Office Address 20103010 Biotechnology Other subject
02 Jun 2020
11:13 CEST 		IMMUPHARMA Notification of Change of AGM Venue 20103010 Biotechnology General meeting / Board Meeting
21 May 2020
09:18 CEST 		IMMUPHARMA Notice of AGM and posting of Report & Accounts Biotechnology General meeting / Board Meeting
14 May 2020
08:45 CEST 		IMMUPHARMA ImmuPharma’s efforts in the fight against Covid-19 with Lupuzor™ and Ureka Biotechnology Products and services
30 Apr 2020
11:13 CEST 		IMMUPHARMA ImmuPharma - Audited Report & Accounts published on website Biotechnology Other subject
30 Apr 2020
08:18 CEST 		IMMUPHARMA ImmuPharma - FINAL RESULTS ANNOUNCEMENT for the twelve months ended 31 December 2019 Biotechnology Other subject
06 Apr 2020
09:37 CEST 		IMMUPHARMA ImmuPharma to present live on ‘Investor Meet Company’ platform Biotechnology Meetings / events
30 Mar 2020
09:19 CEST 		IMMUPHARMA Erratum - Subscription to raise £1.5 million to fund expansion of R&D pipeline Biotechnology Other financial transaction
30 Mar 2020
08:11 CEST 		IMMUPHARMA Subscription to raise £1.5 million To fund expansion of R&D pipeline Biotechnology Other financial transaction
28 Feb 2020
10:02 CET 		IMMUPHARMA Incanthera plc – Admission to trading on the NEX Exchange Growth Market Publication of Admission Document Biotechnology Other subject
17 Feb 2020
09:55 CET 		IMMUPHARMA Oncology specialist Incanthera, in which ImmuPharma currently has a 14.0% shareholding, announces Rule 23 Notice in advance to quoting on NEX Exchange Growth Market Biotechnology Other financial transaction
06 Feb 2020
08:16 CET 		IMMUPHARMA ImmuPharma provides an update on the Avion Agreement in relation to Lupuzor™’s new international Phase III trial Biotechnology Other subject